Advocates' perspective: neoadjuvant chemotherapy for breast cancer.

J Clin Oncol 2012 Dec 19;30(36):4586-8; author reply 4588-9. Epub 2012 Nov 19.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.1824DOI Listing
December 2012

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
4
perspective neoadjuvant
4
breast cancer
4
chemotherapy breast
4
advocates' perspective
4
cancer
1
chemotherapy
1
neoadjuvant
1
advocates'
1
breast
1

Similar Publications

Strategy for nonresponder breast cancer patients to neoadjuvant treatment.

Ann Surg Oncol 2011 Dec 16;18 Suppl 3:S286-7; author reply S288-9. Epub 2011 Aug 16.

View Article and Full-Text PDF
December 2011

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

J Clin Oncol 2012 May 16;30(15):1796-804. Epub 2012 Apr 16.

German Breast Group, c/o GBG Forschungs GmbH, Martin-Behaim-Straße 12, 63263 Neu-Isenburg, Germany.

Purpose: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain.

Methods: Tumor response at surgery and its association with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials were analyzed.

Results: Disease-free survival (DFS) was significantly superior in patients with no invasive and no in situ residuals in breast or nodes (n = 955) compared with patients with residual ductal carcinoma in situ only (n = 309), no invasive residuals in breast but involved nodes (n = 186), only focal-invasive disease in the breast (n = 478), and gross invasive residual disease (n = 4,449; P < . Read More

View Article and Full-Text PDF
May 2012